rorm P	I O-1	1449 Substitute	U.S. Departm	ent of Commerce	Application Number	10/03/,341	
1			Patent and Ti	rademark Office	Filing Date	January 4, 20	002
					First Named Inventor	David Baltimo	ore
INFOR	MAT	TON DISCLOSE	RE STATEM	ENT	Art Unit	1636	
INFORMATION DISCLOSURE STATEM (Ose severe) sheets if necessary)					Examiner Name	C. Hibbert	
OSC SCV	ريحي	dicets if necessar	<i>y)</i>			75723-	
SEP 2 4 2009 B			<del></del>	Attorney Docket No.	ZA/JPW/GJG/C	<u>s</u>	
<b>A</b>	0	<u> </u>	NON PATENT	LITERATURE DOC	UMENTS		
Initials	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate); title of the article (when ap					
	Order issued August 21, 2009 in the concurrent litigation captioned ARIAD Pharmaceuticals, Inc., et al. v. Eli Lilly and Company, U.S. Court of Appeals for the Federal Circuit Docket No. 2008-1248; and  Decision issued June 1, 2009 in the concurrent litigation captioned Amgen, Inc., et al. v. ARIAD Pharmaceuticals, Inc., et al., U.S. Court of Appeals for the Federal Circuit, Docket No. 2009-1023.						
							-
	-						
		<del>-</del>					
EXAMINER SIGNATURE		·		DATE CONSIDERED			
ind not consid	lered. I	al if citation considered, winclude copy of this form wark here if English languag	vith next communicati	is in conformance with MPF ion to applicant. <sup>1</sup> Applicant's ied.	EP 609: Draw line through s unique citation designati	citation if not in conforma on number (optional). <sup>2</sup> App	nce olicant

Applicants: David Baltimore, et al.

Serial No.: 10/037,341 Filed: January 4, 2002

Exhibit A